Nanobiotix S.A. (NASDAQ:NBTX) Sees Significant Drop in Short Interest

Nanobiotix S.A. (NASDAQ:NBTX) was the recipient of a large decline in short interest in the month of September. As of September 30th, there was short interest totalling 33,300 shares, a decline of 18.0% from the September 15th total of 40,600 shares. Based on an average trading volume of 9,500 shares, the short-interest ratio is presently 3.5 days.

Analyst Ratings Changes

Separately, Guggenheim began coverage on Nanobiotix in a research report on Wednesday, August 28th. They issued a “buy” rating and a $12.00 price target on the stock.

Nanobiotix Price Performance

Nanobiotix stock opened at $4.86 on Tuesday. The company’s 50 day simple moving average is $5.11 and its 200 day simple moving average is $5.59. Nanobiotix has a fifty-two week low of $4.14 and a fifty-two week high of $8.96.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.